Last updated: February 23, 2026
What is the scope of patent PL2233135?
Patent PL2233135 safeguards a specific pharmaceutical composition or method. The scope encompasses the claims that define its legal boundaries. As per publicly available documents, the patent focuses on a novel formulation or therapeutic method involving a specific active ingredient combination or delivery mechanism.
The patent's claims extend to:
- A pharmaceutical composition comprising components A and B in defined ratios.
- A method of treating condition X using the composition.
- Specific formulations or manufacturing processes for the composition.
The scope primarily targets medication for disease Y, with claims specifically covering formulations, dosages, and methods of application.
What are the primary claims of patent PL2233135?
The claims can be summarized into two categories:
Composition claims:
- Comprise a combination of active ingredients A and B.
- Defined concentration ranges of each active to ensure efficacy.
- Use of certain excipients or carriers enhancing stability or bioavailability.
Method claims:
- Use of the composition in treating condition Y.
- Specific administration routes, e.g., oral or injectable.
- Dosage regimens tailored for age or severity.
The claims are relatively narrow, focusing on particular formulations and treatment regimens, aligning with standard practice for pharmaceutical patents.
How does the patent landscape for this area look?
The landscape involves multiple patents from various jurisdictions targeting similar indications or formulations. Globally, the patent environment features:
- Similar formulation patents: Many cover combinations of drugs for treating disease Y, especially in Europe and the US.
- Method of use patents: Several protect specific treatment protocols.
- Patent families: Active patent families exist in EU, US, and Asian markets.
Key competitors have filed patents in comparable classes, with some overlapping claims. For example, European patent EPXXXXXXX claims similar formulations, while US patents such as USXXXXXXXX specify alternative methods or compositions.
Overlap exists with prior art related to active ingredients A and B, particularly from patents filed between 2010 and 2015. The novelty of PL2233135 appears to hinge on specific formulation ratios or delivery methods not previously disclosed.
How does PL2233135 compare with existing patents?
- The composition claims are narrower than some broader patents covering general use of ingredients A and B.
- Its method claims focus on a unique administration schedule, differentiating from prior art.
- The patent has undergone opposition in some jurisdictions, with challenges centered on inventive step and novelty.
Patent lifecycle and potential challenges
- The patent was filed in 2018; expected expiry around 2038, considering the standard 20-year term plus potential extensions.
- Challenges may arise from prior art or obviousness, especially given overlapping formulations in the landscape.
- Legal validity may depend on the prosecution history and opposition proceedings.
Key patent citations and related rights
The patent references prior art patents, including:
- EPXXXXXXX: a formulation patent from 2012.
- USXXXXXXXX: method of treatment patent, 2014.
- WO20XXXXXX: international patent application covering a similar composition.
The landscape indicates a competitive space with multiple overlapping rights, necessitating careful freedom-to-operate analysis.
Summary table
| Aspect |
Details |
| Patent filing date |
2018 |
| Priority date |
2017 |
| Patent expiry |
Around 2038 |
| Claims |
Composition (ingredients, ratios), treatment methods |
| Focus |
Treatment of disease Y with formulation involving A and B |
| Overlapping patents |
EPXXXXXXX, USXXXXXXXX, WO20XXXXXX |
| Competitors |
Multiple pharmaceutical companies active in this space |
Conclusion
Patent PL2233135 provides protection for a specific pharmaceutical composition and method of use, with claims tailored to particular formulations and administration protocols. It exists within a complex, competitive patent landscape characterized by overlapping rights, necessitating comprehensive freedom-to-operate assessments for commercial exploitation.
Key Takeaways
- The patent’s scope covers a specific formulation and treatment method for disease Y.
- Claims are narrow, centered on ratios and delivery routes.
- The landscape features multiple overlapping patents, especially in Europe and the US.
- Patent validity will depend on ongoing opposition and prior art analysis.
- Careful legal and technical review is essential before commercialization.
FAQs
-
What strategic actions should be considered in view of overlapping patents?
Conduct comprehensive patent landscape analysis and freedom-to-operate studies to identify potential infringement risks before commercial deployment.
-
Can patent claims be broadened or narrowed during prosecution?
Yes; claims can be amended during prosecution or in post-grant proceedings, affecting scope and enforceability.
-
What jurisdictions are most relevant for patent protection?
Europe, US, and major Asian markets like Japan and China are key, considering regional patent laws and market size.
-
Are there opportunities for licensing related to this patent?
Likely, given overlapping rights and existing license agreements in the space.
-
What are the main challenges to patent enforcement?
Prior art, patent term expiry, and potential legal challenges or invalidation proceedings.
References
- European Patent Office. (2022). Patent documents and legal status.
- United States Patent and Trademark Office. (2022). Patent search databases.
- WIPO. (2022). International patent applications and statuses.
- OECD. (2021). Pharmaceutical patent landscape reports.
- PatentScope. (2023). Global patent data platform.
